IL17A and psoriasis: Moderate-to-severe psoriasis is typically managed with systemic non biologic therapies (like methotrexate and cyclosporin), targeted therapies (such as the oral PDE4 inhibitor apremilast), and biological therapies targeting TNF-α, IL 12/23, IL-17, or IL-23.